Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

  title={Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.},
  author={Bernard R. Chaitman and Sandra L. Skettino and John Orval Parker and Peter Hanley and Jaroslav Meluzin and Jerzy Kuch and Carl J Pepine and Whedy Wang and Jeanenne J. Nelson and David A. Hebert and Andrew A. Wolff},
  journal={Journal of the American College of Cardiology},
  volume={43 8},
OBJECTIVES The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the dose-response relationship of ranolazine, a potentially new anti-anginal compound, on symptom-limited exercise duration. BACKGROUND Fatty acids rise precipitously in response to stress, including acute myocardial ischemia. Ranolazine is believed to partially inhibit fatty acid oxidation, shift metabolism toward carbohydrate oxidation, and increase the efficiency of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 192 extracted citations

Antiarrhythmic properties of novel antianginal drugs in dog and human cardiac preparations PhD Thesis

Szél Tamás, Koncz István, +12 authors András Varró
View 9 Excerpts
Highly Influenced

Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice.

The Journal of pharmacology and experimental therapeutics • 2011
View 6 Excerpts
Highly Influenced

Utility of ranolazine in chronic stable angina patients

Vascular health and risk management • 2008
View 5 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 40 references

[Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology • 2001

Similar Papers

Loading similar papers…